Protagonist Therapeutics, Inc. (PTGX)

Over the past six months, Protagonist Therapeutics' stock has experienced significant movement, with the share price reaching $80.22 as of January 9, 2026, a substantial increase of 115.99% from January 13, 2025, and reaching an all-time high of $96.54 on December 14, 2025. Key events impacting the stock price include the Q3 2025 earnings report with an EPS of -$0.62 and revenue of $4.71 million, the NDA submission for Icotrokinra in July 2025, the NDA submission for Rusfertide in January 2026 following positive Phase 3 data, positive Phase 3 trial data for Icotrokinra in psoriasis, analyst ratings maintaining "Buy" or "Overweight" recommendations with increasing price targets, and disclosures showing strong institutional support. Despite these positive developments, the stock has experienced some daily fluctuations and profit-taking.

Protagonist Therapeutics, as a clinical-stage biopharmaceutical company, does not experience typical demand seasonality. Instead, its progress and financial performance are influenced by clinical trial readouts, regulatory approvals, and strategic partnerships and funding. While some financial platforms may display "PTGX Seasonality" based on historical stock returns, this reflects market trading patterns rather than a seasonal fluctuation in the demand for its specific drug candidates.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative peptide-based new chemical entities to address unmet medical needs, operating within the Healthcare sector and Biotechnology industry, specializing in oral and injectable peptide drugs for hematology and gastroenterology. Its major product candidates include Rusfertide (PTG-300), an injectable hepcidin mimetic in Phase 3 trials for polycythemia vera with an NDA submitted by Takeda and Protagonist in January 2026; Icotrokinra (JNJ-2113), an orally delivered IL-23R antagonist in Phase 3 trials for inflammatory conditions with an NDA submitted in July 2025; PN-943, an orally delivered integrin antagonist that completed Phase 2 trials for ulcerative colitis; PN-235, an injectable IL-23 receptor antagonist for ulcerative colitis in Phase 1b trials; PN-477, a triple agonist anti-obesity peptide in early-stage development; and PN-881, an IL-17 oral peptide antagonist for psoriasis in preclinical stage.

Protagonist Therapeutics, Inc. is headquartered in Newark, California, USA, and maintains a presence in Brisbane, Australia, where its discovery research team is located, reflecting an ambition to be a global company.

Protagonist Therapeutics has built a strong reputation for its expertise in peptide engineering and its commitment to advancing novel treatment options for patients with serious diseases. The company is recognized for its proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates, aiming to provide targeted, often oral, therapies for diseases that traditionally required injectable treatments. The company's reputation has been positively impacted by advancements in its pipeline, positive clinical trial results, and strategic partnerships. However, the biopharmaceutical sector is inherently subject to market volatility and competition, which can influence public perception.

Protagonist Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 113.06% of the stock, followed by Protagonist Therapeutics insiders at 23.55%, and retail investors at 0.00%. Major institutional owners include BlackRock, Inc., Farallon Capital Management LLC, RTW Investments, LP, Vanguard Group Inc., State Street Corp, BVF Inc/Il, Johnson & Johnson, and Wellington Management Group LLP. The largest individual shareholder is Julie Papanek, owning 2.45 million shares, representing 3.92% of the company.